南新制药(688189) - 2022 Q2 - 季度财报

Financial Performance - The company reported a total operating revenue of 400.40 million yuan, a decrease of 7.14% compared to the same period last year[4]. - The total profit for the period was 2.18 million yuan, down 95.43% year-on-year[4]. - The net profit attributable to shareholders was 17.81 million yuan, representing a decline of 57.68% compared to the previous year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 12.24 million yuan, a decrease of 61.21% year-on-year[4]. - The company's operating revenue for the first half of 2022 was approximately RMB 400.40 million, a decrease of 7.14% compared to RMB 431.20 million in the same period last year[24]. - The net profit attributable to shareholders for the first half of 2022 was approximately RMB 17.81 million, down 57.68% from RMB 42.09 million in the previous year[24]. - The basic earnings per share decreased to RMB 0.0909, a decline of 57.68% compared to RMB 0.2147 in the same period last year[23]. - The total profit for the same period was CNY 2.18 million, down 95.43% year-on-year[66]. - The net profit attributable to shareholders was CNY 17.81 million, a decline of 57.68% compared to the previous year[66]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 12.24 million, down 61.21% year-on-year[66]. Research and Development - The company's R&D investment accounted for 7.72% of operating revenue, down 2.68 percentage points from 10.4% in the previous year[23]. - The company has established a product lineup focusing on innovative drugs for major clinical needs, with 34 chemical drug varieties and 53 formulation production approvals, alongside 8 active pharmaceutical ingredient production approvals[31]. - The company is advancing its research pipeline with 8 Class 1 new drug projects, 2 Class 2 modified new drug projects, and 11 Class 3-4 generic drug projects currently under development[31]. - The total R&D investment decreased by 31.11% year-on-year to approximately ¥30.90 million, primarily due to the completion of major R&D work on several projects[49]. - The proportion of capitalized R&D investment increased by 7.00 percentage points to 20.38%, attributed to a decrease in expense-based R&D investment[50]. - The company has applied for 9 new invention patents and obtained 2 during the reporting period, bringing the total number of authorized patents to 32[48]. - The company’s core technologies include drug lead compound design and discovery, lead compound optimization, and chiral drug synthesis, which have not undergone significant changes during the reporting period[47]. - The company has 70 R&D personnel, representing 18.09% of the total workforce, an increase from 54 personnel and 17.65% in the same period last year[58]. Market Challenges - The company faced challenges due to the ongoing COVID-19 pandemic and the implementation of centralized drug procurement policies[4]. - The ongoing COVID-19 pandemic has significantly impacted the demand for the company's core product, "Liwai" (Paramiwe Sodium Chloride Injection), leading to a substantial decrease in sales revenue[63]. - The company is accelerating the development of new markets and enhancing its marketing network to mitigate the impact of the pandemic[64]. - The company faced risks related to the approval of new drugs, with existing products potentially facing market competition from generics[74]. - The ongoing COVID-19 pandemic negatively impacted the company's operations, leading to decreased demand and disruptions in production and sales[73]. Financial Position - The total assets at the end of the reporting period were approximately RMB 2.08 billion, a decrease of 2.24% from RMB 2.13 billion at the end of the previous year[24]. - The company's net assets attributable to shareholders increased by 1.28% to approximately RMB 1.41 billion from RMB 1.39 billion at the end of the previous year[24]. - The company reported a significant increase in interest income to CNY 9,730,127.49, up from CNY 6,073,036.17 in the previous year[191]. - The company reported a net loss of CNY 56,691,426.63, improving from a loss of CNY 74,503,191.29 in the previous period[184]. - Total liabilities decreased from CNY 736,886,724.25 to CNY 682,694,077.01, a reduction of approximately 7.35%[184]. - The total equity attributable to shareholders increased from CNY 1,393,196,824.37 to CNY 1,411,008,589.03, a growth of about 1.28%[184]. Environmental Compliance - The company has established an emergency response plan for environmental incidents in compliance with national regulations and has conducted regular drills[106]. - The company has installed online monitoring facilities for chemical oxygen demand, ammonia nitrogen, and total phosphorus, ensuring real-time pollution discharge monitoring[107]. - The company has complied with environmental protection laws and obtained necessary administrative permits for its projects[104]. - The company has received environmental impact assessment approvals for a project involving the production of 7 tons/year of Palivizumab and two other pharmaceutical raw materials[105]. - The company has not reported any measures taken to reduce carbon emissions during the reporting period[109]. Corporate Governance - The board of directors confirmed that all members attended the meeting and ensured the accuracy and completeness of the report[5]. - The report is unaudited, and the responsible persons have confirmed the financial report's authenticity and accuracy[5]. - The company has not disclosed any significant related party transactions with Nanjing New Pharmaceutical as of the date of the commitment[123]. - The company has committed to timely and full compensation for investor losses if any misleading statements lead to trading losses[132]. - The company will ensure compliance with legal issuance conditions to avoid significant impacts on investors[131].